Evidence map›Paper›PMID 40881497›Full record

ArticleWorld journal of clinical cases2025

Thoughts and challenges of giant retroperitoneal liposarcoma: A case report.

Li-Li Cheng, Biao Tang, Hui Liu, Fan Zhu, Yi-Fa Chen, Wei Zhang

Abstract readCase Reports
In one paragraph

Article in World journal of clinical cases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Li-Li ChengThe First Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China.
Biao TangThe First Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China.
Hui LiuThe First Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China.
Fan ZhuThe First Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China.
Yi-Fa ChenThe First Department of General Surgery, Ezhou Central Hospital, Ezhou 436000, Hubei Province, China.
Wei ZhangHepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 43000, Hubei Province, China. weizhangtjh@hust.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRetroperitoneal liposarcoma (RPLS) is a rare malignant tumor initiated in adipocytes. It is discovered only when the tumor is large because of its deep anatomical location and insidious onset. Giant RPLS with a diameter exceeding 30 cm is extremely rare. Its diagnosis and treatment present extremely great challenges. CASE SUMMARY: The patient, a 62-year-old woman, presented to the hospital complaining of abdominal distension for more than six months. Imaging examination revealed a large retroperitoneal mass. Finally, the patient was diagnosed with giant RPLS. The tumor occupied the entire abdominal cavity, severely compressed the abdominal organs, and adhered tightly to the bilateral ureters. After careful preoperative preparation (including three-dimensional visualization and bilateral ureteral stent implantation), we performed resection of the large retroperitoneal mass. The tumor was completely removed and consisted of multiple masses, with a total weight of 17 kg and the largest mass size of 35 cm × 28 cm × 14 cm. Postoperative pathological results revealed that the mass was a well-differentiated liposarcoma. The patient recovered well after surgery, and there was no sign of recurrence after 2 months of follow-up.

conclusionSurgical resection is the only radical treatment for giant RPLS. Preoperative preparation is essential, and three-dimensional visualization reconstruction is helpful for the formulation of surgical plans. Postoperative radiotherapy and neoadjuvant therapy can be reasonably selected, but whether they can reduce the recurrence rate is still controversial.

Indexed as

Case reportGiantLiposarcomaRetroperitoneal tumorTreatment

Identifiers

PMID40881497
PMCPMC12336901

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.